Input on Social Media Regulatory Guidelines Continues to Trickle in from Life Sciences Companies and Trade Groups
Mark Senak, author of the incisive EyeonFDA blog and de facto watchdog of all things social media in the life sciences, has assiduously been tracking company and trade organization input to the docket for the Part 15 meeting on medical product promotion and the internet and social media. To date, according to Mark, the following companies and trade groups have officially submitted their comments and viewpoints to the docket
- Covidien
- Johnson & Johnson
- Bayer Healthcare
- Sanofi Aventis
- AstraZeneca
- Eli Lilly
- Medtronic
- Pfizer
- Abbott
- Novartis
- Genentech
- Sepracor
- Merck
- Medtronic
- Biotechnology Industry Organization (BIO)
- PhRMA
- National Organization for Rare Disorders (NORD)
As you may recall, industry input was lacking and surprisingly absent from the public hearings held by FDA on the topic earlier this year. While news analysts and bloggers were incredulous that companies didn’t actively participate in the earlier public hearings, this behavior is typical of life sciences companies that like to do things quietly and, when possible, behind closed doors. Ironically, this lack of transparency and inclination to secrecy is the antithesis of social media. Is it any wonder then, that life sciences companies are suspicious and wary of the impact that social media may have on their ability to conduct business?
Until next time...
Good Luck and Good Job Hunting!!!!!!!!
